Ascendis Pharma A (ASND) Total Current Liabilities (2012 - 2026)

Ascendis Pharma A has disclosed Total Current Liabilities across 15 years of filings, most recently posting $1.3 billion for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $1.3 billion, up 41.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 41.62% YoY), and the FY2025 annual result was $1.2 billion, up 57.65% from the prior year.
• Total Current Liabilities came in at $1.3 billion for Q1 2026 at Ascendis Pharma A, up from $1.2 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q1 2026 to a low of $107.0 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $792.4 million (2023), against an average of $658.4 million.
• Across the five-year window, Total Current Liabilities jumped 353.5% in 2023 and decreased 0.36% in 2024, its largest moves.
• Ascendis Pharma A's Total Current Liabilities stood at $174.7 million in 2022, then surged by 353.5% to $792.4 million in 2023, then fell by 0.36% to $789.6 million in 2024, then soared by 57.65% to $1.2 billion in 2025, then climbed by 5.97% to $1.3 billion in 2026.
• The last three Total Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.